The goal of this study was to test the hypotheses that endogenous ADP plays an important role in vivo in mediating platelet aggregation and cyclic coronary artery blood flow variations (CFVs) 67% (four of six) of dogs treated with the combination of apyrase and SQ29548, and 29O (two of seven) of dogs treated with clopidogrel. The plasma epinephrine levels required for CFV restoration were 20 times higher than baseline values in dogs receiving apyrase alone, 100 times higher when a combination of apyrase and SQ29548 had been given, and more than 5,000 times higher in dogs receiving clopidogrel. In vitro studies showed that apyrase only inhibited ADP-induced platelet aggregation, whereas clopidogrel not only inhibited ADP-induced platelet aggregation, but also reduced platelet aggregation induced by the thromboxane mimetic U46619 and serotonin. These data suggest that 1) ADP is an important mediator of platelet aggregation and CFVs in vivo and 2) combined inhibition of thromboxane A2 and ADP's effects provides marked protection against CFVs in experimentally stenosed and endothelium-injured canine coronary arteries. These data and our previous observations are consistent with the possibility that specific antagonists of thromboxane A2, serotonin, and ADP, alone and together, may provide substantial protection against platelet aggregation leading to CFVs at sites of endothelial injury and coronary artery stenosis. (Circulation Research 1992;70:39-48) From the
P latelet aggregation in atherosclerotic coronary
arteries and the release of platelet-derived factors may play an important role in the development of acute coronary artery disease syndromes.1-5 Blockade of the synthesis of thromboxane and inhibition of platelet aggregation by aspirin have been shown to be effective in preventing acute myocardial infarction and death in some patients with unstable angina and also in some healthy persons.67 Experimental studies from this laboratory and others have also shown that receptor antagonists for thromboxane A2 and/or serotonin have potential usefulness in preventing the conversion from chronic stable to unstable coronary disease syndromes. 8 ADP is present in the dense granules of platelets, and it has been shown to be important in mediating platelet aggregation in previous in vitro studies.9-13 Some studies have shown ADP's effect in mediating platelet aggregation in vivo. 14 This study was designed to test the hypothesis that ADP is an in vivo mediator of cyclic coronary artery blood flow variations (CFVs) in a canine model with coronary artery stenosis and endothelial injury and should be added to a list of such mediators that already include thromboxane A2 and serotonin. [1] [2] [3] An animal model, initially described by Folts et al15"16 and characterized by the development of CFVs in stenosed and endothelium-injured arteries, was used to test our hypothesis. An ADP-removing enzyme, apyrase, acting through dephosphorylation of ADP,17 was administered to deplete ADP in the coronary arterial circulation. Another potent inhibitor of ADP-induced platelet aggregation, clopidogrel,18-was also given to some of the animals.
Materials and Methods Surgical Preparation
Thirty mongrel dogs of either sex (25-31 kg) were anesthetized with sodium pentobarbital (30 mg/kg) and ventilated with a mechanical respirator (model 613, Harvard Apparatus, South Natick, Mass.). Plastic catheters were placed into a carotid artery for aortic pressure monitoring and jugular veins for drug and fluid administration. A left fifth intercostal space thoracotomy was performed, and the heart was suspended in a pericardial cradle. A 1-2-cm segment of left anterior descending coronary artery (LAD) was carefully isolated and nearby branches ligated. An ultrasonic Doppler flow probe (Hartley Instruments, Houston, Tex.) was placed around the proximal portion of the isolated segment of the LAD to measure coronary blood flow. In some experiments, a plastic catheter was inserted retrograde into a small branch proximal to the isolated LAD segment for apyrase administration. Another plastic catheter was inserted into a small branch distal to the exposed LAD segment for blood sample collection. Hemodynamics, including heart rates, systolic and diastolic aortic pressures, and phasic and mean coronary blood flow velocities, were continuously recorded on an eight-channel recorder (model 3000, Gould Inc., Cleveland, Ohio).
CFVs were induced by gently squeezing the LAD with cushioned forceps to damage the endothelium and placing a plastic constrictor around the injured portion of the artery. Then, dogs were divided into two groups. Group 1. Sixteen dogs were treated with apyrase (grade V, ATPase 4.1 units/mg, ADPase 3.8 units/ mg; Sigma Chemical Co., St. Louis, Mo.). The drug was delivered into the coronary circulation directly through a catheter positioned in the LAD proximal to the stenosed and endothelium-injured area. The initial dose of apyrase was 0.3 units/min, and it was step-increased to 0.6, 1.2, and 1.8 units/min if CFVs were not completely abolished. After complete abolition of CFVs, the infusion of apyrase was discontinued in some of the dogs at 30 minutes, and saline was infused to determine whether CFVs might recur with time. If CFVs recurred, they were followed for 2 hours and apyrase was infused again in the same manner to determine the correlation between the duration of CFVs and the dosage of apyrase required to abolish them. For some of the dogs (group lb), apyrase infusion was continued and epinephrine was infused intravenously at concentrations of 1.2-17 ,ug/min, attempting to restore CFVs. Thirty minutes after the restoration of CFVs by epinephrine, apyrase infusion was increased to test its effect on epinephrine-restored CFVs. In some studies, SQ29548, a thromboxane A2 receptor antagonist (E.R. Squibb & Sons, Inc., Princeton, N.J.),22 was given as a bolus of 0.2-0.6 mg/kg i.v. and as a sustained infusion of 0.1 mg/kg/hr to dogs in whom apyrase failed to abolish either the initial or the epinephrine-restored CFVs. After SQ29548 abolished CFVs, epinephrine infusion was given attempting to restore CFVs. The dosage of epinephrine required to restore apyrase-abolished or apyrase and SQ29548-abolished CFVs was recorded.
Group 2. Fourteen dogs were treated with clopidogrel (Sanofi Recherche, Toulouse, France) intravenously. Clopidogrel is a methyl-5 (2-chlorophenol)- (4,5,6,7- of CFVs, as indicated by the nadir flow of CFVs, was similar for the two groups of animals ( Table 1) . ADP Concentrations in the Canine LAD Plasma ADP concentrations increased in the canine LAD with 30 minutes of CFVs and increased further with 2 hours of CFVs (Figure 1 ). Apyrase administration reduced ADP concentrations to values comparable to those found before the development of CFVs (Figure 1) .
Effects ofApyrase and Clopidogrel on Cyclic Coronary Blood Flow Variations
The direct administration of apyrase into LADs abolished CFVs in 13 of 16 dogs (81%) with 30 minutes of CFVs. The average dosage of apyrase required to abolish the 30-minute CFVs was 0.4+0.04 units/min (range, 0.3-0.6 units/min). A four times higher dose of apyrase (1.8 units/min) was given to each of the remaining three dogs in whom CFVs continued despite apyrase treatment. Addition of SQ29548, a thromboxane A2 receptor antagonist, abolished CFVs in these three dogs. In six of the dogs (group la) with CFVs abolished by apyrase, saline (1.2-2.4 ml/hr) was infused into the LAD instead of apyrase 30 minutes after CFVs were abolished. Six of the dogs had CFVs restored at an average time of 30 minutes after discontinuation of the apyrase infusion. After 2 hours of consistent CFVs occurring during saline infusion, apyrase was given again by intracoronary infusion. Five of the six dogs (83%) had CFVs abolished once again. However, the dosage of apyrase required to abolish CFVs of 2-hour durations was significantly higher than required for the CFVs of 30-minute duration (1.32±0.12 units/min, p=0.001, Figure 2 ).
Systemic administration of clopidogrel eliminated CFVs in another 14 dogs (100%) with both 30-minute (group 2a) and 3-hour CFVs (group 2b).
Epinephrine-Restored Cyclic Coronary Blood Flow Variations
Seven of the apyrase-treated dogs (group lb) received continuous intravenous infusions of epineph- SQ29548 was needed for the elimination of CFVs, an epinephrine infusion was also given. Four of these six dogs had their CFVs restored by the infusion of epinephrine. The epinephrine dosage required to restore CFVs in these four dogs was 0.6+0.05 ,ug/kg/ min, and it was significantly higher than needed for the restoration of CFVs abolished by apyrase alone (p=0.02, Figure 3 ). These data indicate that combined use of apyrase with SQ29548 may provide more protection against the development of CFVs than apyrase alone. Seven dogs treated with clopidogrel in group 2a received continuous infusions of epinephrine after the abolition of CFVs. Five dogs (71%) did not have CFVs restored by epinephrine infusions. The average dose of epinephrine given to these dogs was 1.3 ± 0.04 ,gg/kg/min. The two dogs with CFVs restored received epinephrine at 1.3 and 1.4 ,g/kg/min, which were greater concentrations of epinephrine than were required to restore CFVs abolished by the combination of apyrase and SQ29548.
Plasma Epinephrine Concentrations
The administration of epinephrine significantly increased plasma epinephrine levels. In dogs treated with apyrase, plasma epinephrine concentrations increased from 0.1±0.02 to 2.3±0.5 ng/ml after the restoration of apyrase-abolished CFVs and to 12±3.7 ng/ml after the restoration of CFVs abolished by apyrase and SQ29548 (p<0.05, Figure 4 ). In dogs treated with clopidogrel, plasma epinephrine increased from 0.1±0.02 to 47 and 54 ng/ml in the two dogs with CFVs restored and to 41±5.6 ng/ml in the dogs in whom CFVs were not restored. These data suggest strong protection against epinephrine- Accumulation of Serotonin Serotonin concentrations in the coronary arteries were measured after clopidogrel and epinephrine in group 2a dogs and clopidogrel alone in group 2b dogs. There were no significant differences in serotonin concentrations in coronary arteries between dogs treated with clopidogrel and epinephrine and clopidogrel alone. However, the LAD segments with stenoses and endothelial injury had 40-fold higher serotonin concentrations in group 2a animals and 58-fold higher in those in group 2b than values in the left circumflex coronary arteries (198±95 versus 5±1 ng/g and 231 ± 114 versus 4±1 ng/g, respectively). The LAD segments proximal and distal to the stenoses also had higher serotonin concentrations than the circumflex coronary arteries, but lower than values in LAD segments with stenoses and endothelial injury.
Platelet Aggregation Studies
The in vitro effect of apyrase on platelet aggregation was evaluated. The IC50 for 10 ,tM ADP-induced platelet aggregation was 0.01 units/ml. At the concentration of 0.1 units/ml, apyrase completely inhibited 20 ,uM ADP-induced platelet aggregation. However, neither 100 ng/ml U46619 nor 1 ,M serotonininduced platelet aggregation was significantly affected by 0.1 units/ml apyrase ( Figure 5 ). In clopidogrel-treated dogs, ADP platelet aggregation was completely inhibited after in vivo administration of clopidogrel. Serotonin and U46619-induced platelet aggregation were also inhibited approximately 70% and 40%, respectively ( Figure  SB) . These data suggest that apyrase is relatively specific in inhibiting ADP-induced platelet aggregation, while clopidogrel's antiplatelet effects in dogs are complex and include an ability to prevent ADPinduced platelet aggregation as well as partial inhibitory effect on thromboxane A2 and serotonin-induced platelet aggregation.
Blood Coagulation Studies Activated whole-blood clotting times and partial thromboplastin times were measured before and 15 minutes after clopidogrel. Activated whole-blood clotting times were prolonged from 125 + 1 to 148+9 seconds and partial thromboplastin times from 38±3 to 48±5 seconds (p<0.05 for both), thereby indicating a mild anticoagulant effect of clopidogrel.
Discussion
The data from the present study suggest that ADP is a mediator of platelet aggregation and CFVs in stenosed and endothelium-injured canine coronary arteries.
Cyclic Coronary Blood Flow Variations
At sites of arterial stenosis and endothelial injury, recurrent platelet aggregation and dislodgment lead- inhibiting the synthesis of thromboxane A2 and blocking the activation of thromboxane A2 and serotonin receptors appears to provide more complete protection against epinephrine-restored CFVs in experimental canine models. 34, 43 In the present study, epinephrine infusion restored CFVs that had been abolished by apyrase alone in each of seven dogs. The plasma epinephrine concentrations required to restore CFVs were more than 20 times baseline levels. This suggests that removal of ADP from the coronary circulation and inhibiting ADP-induced platelet aggregation alone may provide protection against epinephrine-enhanced platelet aggregation, but it does not completely prevent it. As SQ29548 was added to apyrase, the incidence of CFV restoration was reduced and the plasma epinephrine concentrations required to restore CFVs were higher than for apyrase treatment alone. Therefore, the combination of a thromboxane A2 receptor antagonist and reductions in ADP concentrations in the coronary artery circulation may provide stronger protection than just reducing ADP concentrations alone. Clopidogrel prevented CFV restoration by epinephrine in five of seven dogs. However, it appears to have a broad spectrum of antagonism, including serving as an antagonist of ADP, thromboxane A2, and serotonin-induced platelet aggregation, thereby possibly accounting for its pronounced protective effect. In conclusion, the data obtained in the present study suggest that ADP plays an important role in mediating platelet aggregation-associated CFVs in experimentally stenosed and endothelium-injured canine coronary arteries. Therefore, it should be included with thromboxane A2 and serotonin as important mediators of CFVs in this experimental model. Reducing ADP concentrations in the coronary circulation and inhibiting ADP's ability to stimulate platelet aggregation may prevent coronary artery thrombosis in stenosed and endothelium-injured coronary arteries and provide protection against epinephrineenhanced platelet aggregation and thrombosis in vivo. A combination of inhibition of ADP-induced platelet aggregation with antagonism of thromboxane A2 receptors provides more protection than inhibiting ADP's ability to stimulate platelet aggregation alone in this experimental model. Clopidogrel is effective in preventing CFVs and provides protection against epinephrine-enhancing CFVs. This protective effect appears to result from its ability to antag-onize the ability of ADP, serotonin, and thromboxane A2 to stimulate platelet aggregation.
